Cannabinoid-mediated regulation of the hypothalamopituitary-adrenal axis in rats: Age dependent role of vasopressin

Endocrine Regulations

Volumn 43, Issue 1, 2009, Pages 13-21

  Barna, Istvan ^a   Csabai, Katalin ^a   Makara, Gabor B ^a   Zelena, Dora ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

ACTH; Adulthood; Corticosterone; Neonatal period; Vasopressin; WIN 55,212 2

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID; CORTICOSTERONE; CORTICOTROPIN; VASOPRESSIN; ARGIPRESSIN; BENZOXAZINE DERIVATIVE; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE;

AGE DISTRIBUTION; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CORTICOTROPIN BLOOD LEVEL; CORTICOTROPIN RELEASE; HORMONE ACTION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; NONHUMAN; RAT; REGULATORY MECHANISM; ADRENAL GLAND; AGING; ANIMAL; BLOOD; BRATTLEBORO RAT; DRUG EFFECT; HYPOPHYSIS; HYPOTHALAMUS; PHYSIOLOGY; WISTAR RAT;

ADRENAL GLANDS; ADRENOCORTICOTROPIC HORMONE; AGING; ANIMALS; ARGININE VASOPRESSIN; BENZOXAZINES; CANNABINOIDS; CORTICOSTERONE; HYPOTHALAMUS; MALE; MORPHOLINES; NAPHTHALENES; PITUITARY GLAND; RATS; RATS, BRATTLEBORO; RATS, WISTAR;

EID: 67650000927     PISSN: 12100668     EISSN: 13360329     Source Type: Journal    
DOI: 10.4149/endo_2009_01_13     Document Type: Article

References (45)

1. ANTONI FA: Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front Neuroendocrinol 14, 76-122, 1993
2. AVISHAI-ELINER S, YI SJ, NEWTH CJ, BARAM TZ: Effects of maternal and ibling deprivation on basal and stress induced hypothalamic-pituitary-adrenal components in the infant rat. Neurosci Lett 192, 49-52, 1995
3. BARNA I, ZELENA D, ARSZOVSZKI AC, LEDENT C: The role of endogenous cannabinoids in the hypothalamo-pituitaryadrenal axis regulation: in vivo and in vitro studies in CB1 receptor knockout mice. Life Sci 75, 2959-2970, 2004
4. BOHUS B, DE WIED D: The vasopressin deficient Brattleboro rats: a natural knockout model used in the search for CNS effects of vasopressin. Prog Brain Res 119, 555-573, 1998
5. BORCEL E, PEREZ-ALVAREZ L, DE CEBALLOS ML, Ramirez BG, Marco EM, Fernandez B, Rubio M, Guaza C, Viveros MP: Functional responses to the cannabinoid agonist WIN 55,212-2 in neonatal rats of both genders: influence of weaning. Pharmacol Biochem Behav 78, 593-602, 2004
6. BROWN TT, DOBS AS: Endocrine effects of marijuana. J Clin Pharmacol 42, 90S-96S, 2002
7. BUCKLEY NE, HANSSON S, HARTA G, MEZEY E: Expression of the CB1 and CB2 receptor messenger RNAs during embryonic development in the rat. Neuroscience 82, 1131-1149, 1998
8. DE KLOET ER: Hormones, brain and stress. Endocr Regul 37, 51-68, 2003
9. DEVANE WA, HANUS L, BREUER A, OERTWEE RG, STEVENSON LA, MENDELBAUM A, ETINGER A, MECHOULAM R: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949, 1992
10. DI S, MALCHER-LOPES R, HALMOS KC, TASKER JG: Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. J Neurosci 23, 4850-4857, 2003
11. EVANS DA, DE BREE FM, NIJENHUIS M, VAN DER KLEIJ AA, ZALM R, KORTEWEG N, VAN LEUVEREN FW, BURBACH JP: Processing of frameshifted vasopressin precursors. J Neuroendocrinol 12, 685-693, 2000
12. GERSTBERGER R, FAHRENHOLZ F: Autoradiographic localization of V1 vasopressin binding sites in rat brain and kidney. Eur J Pharmacol 167, 105-116, 1989
13. GRINO M, BURGUNDER JM, ESKAY RL, EIDEN LE: Onset of glucocorticoid responsiveness of anterior pituitary corticotrophs during development is scheduled by corticotropin-releasing factor. Endocrinology 124, 2686-2692, 1989
14. GUNNAR MR, DONZELLA B: Social regulation of the cortisol levels in early human development. Psychoneuroendocrinology 27, 199-220, 2002
15. HERKENHAM M, LYNN AB, JOHNSON MR, MELVIN LS, DE COSTA BR, RICE KC: Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11, 563-583, 1991
16. HOWLETT AC: The cannabinoid receptors. Prostaglandins Other Lipid Mediat 68-69, 619-631, 2002
17. KOFALVI A, VIZI ES, LEDENT C, SPERLAGH B: Cannabinoids inhibit the release of [3H]glutamate from rodent hippocampal synaptosomes via a novel CB1 receptor-independent action. Eur J Neurosci 18, 1973-1978, 2003
18. LEVINE S: Regulation of the hypothalamic-pituitary-adrenal axis in the neonatal rat: the role of maternal behavior. Neurotox Res 4, 557-564, 2002
19. MAKARA GB, MERGL Z, ZELENA D: The role of vasopressin in hypothalamo-pituitary-adrenal axis activation during stress: an assessment of the evidence. Ann N Y Acad Sci 1018, 151-161, 2004
20. MANZANARES J, CORCHERO J, FUENTES JA: Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta(9)-tetrahydrocannabinol in rats. Brain Res 839, 173-179, 1999
21. MARTIN-CALDERON JL, MUNOZ RM, VILLANUA MA, DEL ARCO I, MORENO JL, DE FONSECA FR, MAVARRO M: Characterization of the acute endocrine actions of (-)-11-hydroxy-delta8-tetrahydrocannabinol-dimethylheptyl (HU-210), a potent synthetic cannabinoid in rats. Eur J Pharmacol 344, 77-86, 1998
22. MATSUDA LA, LOLAIT SJ, BROWNSTEIN MJ, YOUNG AC, BONNER TI: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564, 1990
23. MECHOULAM R, BEN-SHABAT S, HANUS L, LIGUMSKY M, KAMINSKY NE, SHATZ AR, GOPHER A, ALMOG S, MARTIN BR, COMPTON DR: Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50, 83-90, 1995
24. MLYNARIK M, ZELENA D, BAGDY G, MAKARA GB, JEZOVA D: Signs of attenuated depression-like behavior in vasopressin deficient Brattleboro rats. Horm Behav 51, 395-405, 2007
25. MUNRO S, THOMAS KL, ABU-SHAAR M: Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65, 1993
26. MURET L, PRIOU A, OLIVER C, GRINO M: Stimulation of adrenocorticotropin secretion by insulin-induced hypoglycemia in the developing rat involves arginine vasopressin but not corticotropin-releasing factor. Endocrinology 130, 2725-2732, 1992
27. NIEDERHOFFER N, HANSEN HH, FERNANDEZ-RUIZ JJ, SZABO B: Effects of cannabinoids on adrenaline release from adrenal medullary cells. Br J Pharmacol 134, 1319-1327, 2001
28. ONAIVI ES, ISHIGURO H, GONG JP, et al.: Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci 1074, 514-536, 2006
29. PORTER AC, FELDER CC: (2001): The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol Ther 90, 45-60, 2001
30. PUDER M, WEIDENFELD J, CHOWERS I, NIR I, CONFORTI N, SIEGEL RA: Corticotrophin and corticosterone secretion following delta 1-Tetrahydrocannabinol, in intact and in hypothalamic deafferentated male rats. Exp Brain Res 46, 85-88, 1982
31. REDEI E, PARE WP, AIRD F, KLUCZYNSKI J: Strain differences in hypothalamic-pituitary-adrenal activity and stress ulcer. Am J Physiol 266, R353-360, 1994
32. ROMERO EM, FERNANDEZ B, SAGREDO O, GOMEZ N, URIGUEN L, GUAYA C, DE MIGUEL R, RAMOS JA, VIVEROS MP: Antinociceptive, behavioural and neuroendocrine effects of CP 55,940 in young rats. Brain Res Dev Brain Res 136, 85-92, 2002
33. SAPOLSKY RM, KREY LC, MCEWEN BS: The neuroendocrinology of stress and aging: the glucocorticoid cascade hypothesis. Endocrine Rev 7, 284-301, 1986
34. SAPOLSKY RM, KREY LC, MCEWEN BS, RAINBOW TC: Do vasopressin-related peptides induce hippocampal corticosterone receptors? Implications for aging. J Neurosci 4, 1479-1485, 1984
35. Sawzdargo M, Nguyen T, Lee DK, Lynch KR, Cheng R, Heng HH, George SR, O'Dont BF: Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res Mol Brain Res 64, 193-198, 1999
36. SCOTT LV, DINAN TG: Vasopressin and the regulation of hypothalamic-pituitary-adrenal axis function: implications for the pathophysiology of depression. Life Sci 62, 1985-1998, 1998
37. TRIBOLLET E, GOUMAZ M, RAGGENBASS M, DUBOIS-DAUPHIN M, DREIFUSS JJ: Early appearance and transient expression of vasopressin receptors in the brain of rat fetus and infant. An autoradiographical and electrophysiological study. Brain Res Dev Brain Res 58, 13-24, 1991
38. TSOU K, BROWN S, SANUDO-PENA MC, MACKIE K, WALKER JM: Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83, 393-411, 1998
39. WALKER CD, SAPOLSKY RM, MEANEY MJ, VALE WW, RIVIER CL: Increased pituitary sensitivity to glucocorticoid feedback during the stress nonresponsive period in the neonatal rat. Endocrinology 119, 1816-1821, 1986
40. WENGER T, JAMALI KA, JUANEDA C, LEONARDELLI J, TRAMU G: Arachidonyl ethanolamide (anandamide) activates the parvocellular part of hypothalamic paraventricular nucleus. Biochem Biophys Res Commun 237, 724-728, 1997
41. WENGER T, LEDENT C, TRAMU G: The endogenous cannabinoid, anandamide, activates the hypothalamo-pituitary-adrenal axis in CB1 cannabinoid receptor knockout mice. Neuroendocrinology 78, 294-300, 2003
42. Wotjak CT, Ludwig M, Ebner K, Russel JA, Singewald N, Landgraf R: Vasopressin from hypothalamic magnocellular neurons has opposite actions at the adenohypophysis and in the supraoptic nucleus on ACTH secretion. Eur J Neurosci 16, 477-485, 2002
43. ZELENA D, MAKARA GB, JEZOVA D: Simultaneous blockade of two glutamate receptor subtypes (NMDA and AMPA) results in stressor-specific inhibition of prolactin and corticotropin release. Neuroendocrinology 69, 316-323, 1999
44. ZELENA D, MERGL Z, MAKARA GB: Maternal genotype influences stress reactivity of vasopressin-deficient Brattleboro rats. J Neuroendocrinol 15, 1105-1110, 2003
45. ZELENA D, MERGL Z, MAKARA GB: The role of vasopressin in diabetes mellitus-induced hypothalamo-pituitary-adrenal axis activation: studies in Brattleboro rats. Brain Res Bull 69, 48-56, 2006